DK2595484T3 - Anvendelse af cykliske amidderivater til behandling af søvnforstyrrelser - Google Patents
Anvendelse af cykliske amidderivater til behandling af søvnforstyrrelser Download PDFInfo
- Publication number
- DK2595484T3 DK2595484T3 DK11810349.8T DK11810349T DK2595484T3 DK 2595484 T3 DK2595484 T3 DK 2595484T3 DK 11810349 T DK11810349 T DK 11810349T DK 2595484 T3 DK2595484 T3 DK 2595484T3
- Authority
- DK
- Denmark
- Prior art keywords
- group
- sleep
- compound
- schizophrenia
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/0001—Arrangements for dividing the transmission path
- H04L5/0003—Two-dimensional division
- H04L5/0005—Time-frequency
- H04L5/0007—Time-frequency the frequencies being orthogonal, e.g. OFDM(A), DMT
- H04L5/001—Time-frequency the frequencies being orthogonal, e.g. OFDM(A), DMT the frequencies being arranged in component carriers
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/0001—Arrangements for dividing the transmission path
- H04L5/0014—Three-dimensional division
- H04L5/0016—Time-frequency-code
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/0001—Arrangements for dividing the transmission path
- H04L5/0014—Three-dimensional division
- H04L5/0016—Time-frequency-code
- H04L5/0019—Time-frequency-code in which one code is applied, as a temporal sequence, to all frequencies
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/003—Arrangements for allocating sub-channels of the transmission path
- H04L5/0048—Allocation of pilot signals, i.e. of signals known to the receiver
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/003—Arrangements for allocating sub-channels of the transmission path
- H04L5/0048—Allocation of pilot signals, i.e. of signals known to the receiver
- H04L5/005—Allocation of pilot signals, i.e. of signals known to the receiver of common pilots, i.e. pilots destined for multiple users or terminals
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/003—Arrangements for allocating sub-channels of the transmission path
- H04L5/0053—Allocation of signaling, i.e. of overhead other than pilot signals
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Signal Processing (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Computer Networks & Wireless Communication (AREA)
- Psychiatry (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (11)
1. Forbindelse med formlen (II) eller farmaceutisk acceptabelt salt, hydrat eller solvat deraf til anvendelse i behandling eller bedring af mindst én søvnforstyrrelse hos en person, der lider af skizofreni: II
2. Forbindelse eller salt, hydrat eller solvat deraf til anvendelse ifølge krav 1, hvor personen lider af mindst ét symptom på skizofreni udvalgt fra gruppen bestående af et positivt symptom på skizofreni, et negativt symptom på skizofreni og et generelt symptom på skizofreni.
3. Forbindelse eller salt, hydrat eller solvat deraf til anvendelse ifølge krav 2, hvor det negative symptom er udvalgt fra gruppen bestående af et primært negativt symptom og et sekundært negativt symptom.
4. Forbindelse eller salt, hydrat eller solvat deraf til anvendelse ifølge krav 1, hvor personen er en effektiv cytochrom P450 2D6-metabolisator.
5. Sammensætning til anvendelse i behandling eller bedring af mindst én søvnforstyrrelse hos en person, der lider af skizofreni, hvilken sammensætning omfatter: (a) en terapeutisk effektiv mængde af en antipsykotisk forbindelse, der ikke er en forbindelse med formlen (I); og (b) en terapeutisk effektiv mængde af en forbindelse med formlen (II) ifølge krav 1, eller et farmaceutisk acceptabelt salt, hydrat eller solvat deraf, hvor den terapeutisk effektive mængde af en antipsykotisk forbindelse, der ikke er en forbindelse med formlen (I), er lavere end den ellers ville være i fravær af forbindelsen med formlen (II), hvor forbindelsen med formlen (I) er
hvor: X repræsenterer en alkylgruppe, en cycloalkyl-substitueret alkylgruppe, en aryl-substitueret alkylgruppe, en aryl-substitueret alkenylgruppe, en aryl-substitueret alkynylgruppe, en monocyklisk eller polycyklisk cycloalkylgruppe, der kan være substitueret med en alkylgruppe, en arylgruppe, en heterocyklisk gruppe eller en substitueret eller usubstitueret aminogruppe; Q repræsenterer en gruppe repræsenteret ved —CO—, —O—, —S—, — CH(OR.7)—, —C(=CH2)— eller — C(=NRs)—, hvor R7 repræsenterer et hydrogenatom, en alkylgruppe, en hydroxyalkylgruppe, eller en acylgruppe, og Rs repræsenterer en hydroxylgruppe, en alkoxylgruppe, en aralkyloxygruppe, en acyloxygruppe, en acylaminogruppe eller en alkoxycarbonylaminogruppe; n repræsenterer et heltal på fra 0 til 5; Ri og R2 hver uafhængigt repræsenterer et hydrogenatom eller en alkylgruppe; B repræsenterer følgende grupper:
hvor R3, R4, Rs og R6 hver uafhængigt repræsenterer en substituent udvalgt fra gruppen bestående af et hydrogenatom, et halogenatom, en nitrogruppe, en alkylgruppe, en halogeneret alkylgruppe, en hydroxylgruppe, en alkoxylgruppe, en halogeneret alkoxylgruppe og en cyangruppe; m repræsenterer 1 eller 2.
6. Forbindelse eller salt, hydrat eller solvat deraf til anvendelse ifølge et hvilket som helst af kravene 1-4, hvor den mindst ene søvnforstyrrelse er udvalgt fra gruppen bestående af latenstid til søvnstart, latenstid til dyb søvn, og fordelingen af slow-wave-søvn over søvnperioden eller ét eller flere segmenter af søvnperioden.
7. Forbindelse eller salt, hydrat eller solvat deraf til anvendelse ifølge et hvilket som helst af kravene 1-4, hvor bedringen omfatter bedring af latenstid til søvnstart eller latenstid til dyb søvn.
8. Forbindelse eller salt, hydrat eller solvat deraf til anvendelse ifølge et hvilket som helst af kravene 1-4, hvor bedringen omfatter en stigning i slow-wave-søvn i den første tredjedel af søvnperioden.
9. Sammensætning til anvendelse ifølge krav 5, hvor den mindst ene søvnforstyrrelse er udvalgt fra gruppen bestående af latenstid til søvnstart, latenstid til dyb søvn, og fordelingen af slow-wave-søvn over søvnperioden eller ét eller flere segmenter af søvnperioden.
10. Sammensætning til anvendelse ifølge krav 5, hvor bedringen omfatter bedring af latenstid til søvnstart eller latenstid til dyb søvn.
11. Sammensætning til anvendelse ifølge krav 5, hvor bedringen omfatter en stigning i slow-wave-søvn i den første tredje del af søvnperioden.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36607510P | 2010-07-20 | 2010-07-20 | |
| PCT/US2011/044697 WO2012012542A1 (en) | 2010-07-20 | 2011-07-20 | Methods of use of cyclic amide derivatives to treat schizophrenia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2595484T3 true DK2595484T3 (da) | 2018-01-22 |
Family
ID=45497166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11810349.8T DK2595484T3 (da) | 2010-07-20 | 2011-07-20 | Anvendelse af cykliske amidderivater til behandling af søvnforstyrrelser |
| DK16181339.9T DK3135286T3 (da) | 2010-07-20 | 2011-07-20 | Fremgangsmåder til anvendelse af cykliske amidderivater til behandling af skizofreni og symptomer derpå |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16181339.9T DK3135286T3 (da) | 2010-07-20 | 2011-07-20 | Fremgangsmåder til anvendelse af cykliske amidderivater til behandling af skizofreni og symptomer derpå |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20180155318A1 (da) |
| EP (3) | EP3335731A1 (da) |
| JP (2) | JP6053678B2 (da) |
| KR (1) | KR101867633B1 (da) |
| CN (1) | CN103220910B (da) |
| BR (1) | BR112013001303A2 (da) |
| CA (2) | CA3117855C (da) |
| DK (2) | DK2595484T3 (da) |
| ES (2) | ES2963362T3 (da) |
| FI (1) | FI3135286T3 (da) |
| HR (1) | HRP20231446T1 (da) |
| HU (1) | HUE064157T2 (da) |
| LT (1) | LT3135286T (da) |
| NO (1) | NO2595484T3 (da) |
| PL (2) | PL3135286T3 (da) |
| PT (2) | PT2595484T (da) |
| RS (1) | RS64819B1 (da) |
| RU (1) | RU2576611C2 (da) |
| SI (1) | SI3135286T1 (da) |
| TW (1) | TWI583679B (da) |
| WO (1) | WO2012012542A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2968977A1 (en) * | 2014-12-02 | 2016-06-09 | Minerva Neurosciences, Inc. | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
| TWI820001B (zh) * | 2016-05-25 | 2023-11-01 | 日商田邊三菱製藥股份有限公司 | 醫藥組成物的用於製造非思覺失調症病患之負性症狀治療劑的用途 |
| CN116492340A (zh) | 2017-10-10 | 2023-07-28 | 纽罗克里生物科学有限公司 | 施用某些vmat2抑制剂的方法 |
| AU2019326525A1 (en) * | 2018-08-21 | 2021-03-04 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3888340T2 (de) * | 1988-01-21 | 1994-06-30 | Merrell Dow Pharma | Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit. |
| KR927002347A (ko) * | 1989-10-27 | 1992-09-03 | 레이몬드 지. 아너 | (n-프탈이미도알킬) 피페리딘 |
| NZ235841A (en) * | 1989-10-27 | 1993-03-26 | Du Pont | (n-phthalimidoalkyl) piperidine derivatives and pharmaceutical compositions |
| CA2401711C (en) * | 2000-02-29 | 2008-06-03 | Mitsubishi Pharma Corporation | Cyclic amide derivatives |
| US7626056B2 (en) * | 2005-06-06 | 2009-12-01 | Merck Sharp & Dohme Limited | Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
-
2011
- 2011-07-20 EP EP17196800.1A patent/EP3335731A1/en active Pending
- 2011-07-20 ES ES16181339T patent/ES2963362T3/es active Active
- 2011-07-20 PT PT118103498T patent/PT2595484T/pt unknown
- 2011-07-20 EP EP16181339.9A patent/EP3135286B1/en active Active
- 2011-07-20 TW TW100125661A patent/TWI583679B/zh active
- 2011-07-20 RS RS20231061A patent/RS64819B1/sr unknown
- 2011-07-20 NO NO11810349A patent/NO2595484T3/no unknown
- 2011-07-20 LT LTEP16181339.9T patent/LT3135286T/lt unknown
- 2011-07-20 HU HUE16181339A patent/HUE064157T2/hu unknown
- 2011-07-20 KR KR1020137004217A patent/KR101867633B1/ko active IP Right Grant
- 2011-07-20 PT PT161813399T patent/PT3135286T/pt unknown
- 2011-07-20 EP EP11810349.8A patent/EP2595484B1/en active Active
- 2011-07-20 JP JP2013520840A patent/JP6053678B2/ja active Active
- 2011-07-20 SI SI201132096T patent/SI3135286T1/sl unknown
- 2011-07-20 FI FIEP16181339.9T patent/FI3135286T3/fi active
- 2011-07-20 CA CA3117855A patent/CA3117855C/en active Active
- 2011-07-20 PL PL16181339.9T patent/PL3135286T3/pl unknown
- 2011-07-20 RU RU2013107382/15A patent/RU2576611C2/ru active
- 2011-07-20 CN CN201180045067.1A patent/CN103220910B/zh active Active
- 2011-07-20 BR BR112013001303A patent/BR112013001303A2/pt not_active Application Discontinuation
- 2011-07-20 DK DK11810349.8T patent/DK2595484T3/da active
- 2011-07-20 ES ES11810349.8T patent/ES2656313T3/es active Active
- 2011-07-20 DK DK16181339.9T patent/DK3135286T3/da active
- 2011-07-20 HR HRP20231446TT patent/HRP20231446T1/hr unknown
- 2011-07-20 WO PCT/US2011/044697 patent/WO2012012542A1/en active Application Filing
- 2011-07-20 PL PL11810349T patent/PL2595484T3/pl unknown
- 2011-07-20 CA CA2806017A patent/CA2806017C/en active Active
-
2016
- 2016-08-23 JP JP2016163049A patent/JP6200561B2/ja active Active
-
2017
- 2017-07-21 US US15/656,062 patent/US20180155318A1/en not_active Abandoned
-
2022
- 2022-05-16 US US17/745,024 patent/US20220274951A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9732059B2 (en) | Methods of use of cyclic amide derivatives to treat schizophrenia | |
| US20220274951A1 (en) | Methods of use of cyclic amide derivatives to treat schizophrenia | |
| JP6419294B2 (ja) | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 | |
| WO2024107681A1 (en) | Methods of switching neuropsychiatric medications using ulotaront | |
| WO2023219548A1 (en) | Selective dopamine increase |